Poxel To Sell PXL770 To Scynexis For Up To $196 Mln; Shares Up
(RTTNews) - Poxel SA (POXEL.PA, PXXLF), a clinical-stage biopharmaceutical company, on Tuesday announced that it has agreed to sell its drug candidate PXL770 to Scynexis, Inc. (SCYX), for up to $196 million...
Nasdaq News: Markets·11d ago